CVRx, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $44.5M
- Price
- $1.67
- % Change (Daily % change from the live per-ticker quote feed.)
- +3.09%
- Volume
- 896.6K
About
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
Quick stats
Shares outstanding26.6M
Computed float14.0M
Float / shares52.6%
Cash runway (months)15.6
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001235912
Websitehttps://www.barostim.com
AI Summary
AI-generated1/44
minorneutrallegal litigation
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop
Hagens Berman announced an investigation into CVRx for potential securities-law violations, soliciting investors with substantial losses to contact the firm.
The probe follows CVRx's August 6, 2026 disclosures of a DOJ Civil Investigative Demand, a major 2026 revenue guidance cut, sales-force disruption, and a Medicare Advantage payer approval-rate collapse from 80% to 25% — after which the stock fell 59%.
CVRx also terminated its Chief Revenue Officer Robert John on August 10, 2026, which the firm is examining for links to the DOJ CID.
The release is plaintiff-firm marketing rather than issuer disclosure; treat the underlying DOJ and commercial issues as already public.
Red flags
- DOJ Civil Investigative Demand into potential false claims, kickbacks, and improper marketing of Barostim
- 59% single-day stock collapse on August 7, 2026
- Medicare Advantage 30-day approval rate collapsed from 80% to 25%
- sudden termination of Chief Revenue Officer three days after disclosures
- significant 2026 revenue guidance cut amid sales-force turnover